Vertex Pharmaceuticals Analysts Raise Their Forecasts Following Q3 Results
Vertex missed Q3 EPS estimates but beat sales, raised FY2026 guidance, and shares rose 2.7% as analysts lifted price targets.
Share
Why It Matters
Vertex made more money than expected from selling medicine this quarter. Experts now think the company will do better next year, so that's why they raised their price targets.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.